Intellia Therapeutics Inc (NTLA)

Nov 5, 2026

Intellia Therapeutics reported its third-quarter 2026 financial results and provided business updates, highlighting significant progress in its late-stage pipeline. The company is on track for the potential approval and commercial launch of lonvo-z, its one-time CRISPR-based therapy for Hereditary Angioedema (HAE), in early 2027. Intellia also completed enrollment for a Phase 3 trial of nex-z for ATTRv-PN and secured a $400 million term loan facility, extending its cash runway into 2028.

Nov 5, 2026

Intellia Therapeutics ($NTLA) reported its Q3 2026 earnings, missing both earnings per share and revenue estimates. The company reported an EPS of -$0.91 against an -$0.81 estimate and revenue of $7.16 million against a $10.67 million estimate. Insider trading activity for NTLA over the past six months shows seven sales and no purchases by executives, while institutional investors showed mixed activity, with 182 adding shares and 119 decreasing positions.

Nov 3, 2026

Intellia Therapeutics will present new clinical data for nexiguran ziclumeran (nex-z) at two medical meetings in November. The presentations will include cardiac outcomes from a Phase 1 trial in ATTRv-PN patients with mixed phenotype at the American Heart Association Scientific Sessions and long-term follow-up data from the Phase 1 trial in ATTRv-PN patients at the International Society of Amyloidosis 2026 Symposium. Nex-z is a CRISPR/Cas9 gene-editing therapy being investigated as a potential one-time treatment for ATTR amyloidosis.